Strategic Collaborations Leverage existing and past partnerships with Rutgers, NHLBI, Atlas Antibodies and international entities to position T-Cure as a collaborative partner for co-development, clinical trials infrastructure, and supply agreements, expanding access to translational and late-stage opportunities.

KK-LC-1 Targeting Position KK-LC-1 focused TCR-T programs as a differentiator for solid tumors including gastric, cervical, lung, and breast cancers; target pharma/biotech entities seeking novel antigen-specific therapies with pipeline expansion potential.

Companion Diagnostics Promote opportunities around companion tests for HERV-E transcripts to accompany TCR-T therapies, offering integrated biomarker-enabled trial designs and precision patient selection services for partner programs.

Autologous TCR-T Capabilities Highlight autologous TCR-T platform strength and iSORT discovery capabilities as a value-add for partners seeking rapid discovery-to-candidate workflows, potentially accelerating partner programs and reducing development timelines.

Funding and David-Scale Fit Target mid-sized biotech and academia-industry collaborations that align with revenue and funding profiles (1M–10M revenue range) to pursue joint development, manufacturing partnerships, and sponsored research leveraging T-Cure’s early-stage traction.